Breaking News Instant updates and real-time market news.

GKOS

Glaukos

$61.17

-5.23 (-7.88%)

, SWAV

ShockWave Medical

$29.72

-1.97 (-6.22%)

09:29
09/30/19
09/30
09:29
09/30/19
09:29

Glaukos downgraded to Underperform from Buy at BofA/Merrill

BofA/Merrill analyst Bob Hopkins double downgraded Glaukos (GKOS) to Underperform from Buy and lowered his price target for the shares to $67 from $75. The analyst remains bullish on the company's long term prospects and sees no issues with its Q3 and Q4 results, but he prefers other names in the space given the potential distraction associated with the integration of Avedro. Hopkins also lowered his price target for ShockWave Medical (SWAV) to $40 from $64 and for Intersect ENT (XENT) to $22 from $39.

GKOS

Glaukos

$61.17

-5.23 (-7.88%)

SWAV

ShockWave Medical

$29.72

-1.97 (-6.22%)

XENT

Intersect ENT

$16.54

-0.19 (-1.14%)

  • 13

    Nov

GKOS Glaukos
$61.17

-5.23 (-7.88%)

08/13/19
SPHN
08/13/19
NO CHANGE
Target $95
SPHN
Overweight
Glaukos pullback provides buying opportunity, says Stephens
Stephens analyst Chris Cooley believes investors should take advantage of the recent pullback in Glaukos (GKOS) shares, arguing that the company's existent new product pipeline plus the potential total addressable market expansion from the company's planned Avedro (AVDR) acquisition "more than merits" a roughly 25% relative valuation premium. Combining the companies results in a roughly 450 basis points increase to reported growth in calendar 2021 before factoring in the opportunity for potential revenue synergies, contributions from planned new products, expanded indications for use or geographic expansion, said Cooley, who maintains his $95 price target and Overweight rating on Glaukos shares.
08/14/19
JPMS
08/14/19
DOWNGRADE
Target $26
JPMS
Neutral
JPMorgan downgrades Avedro to Neutral, says another suitor unlikely
JPMorgan analyst Robbie Marcus downgraded Avedro (AVDR) to Neutral from Overweight with an unchanged price target of $26. Another suitor emerging to compete with Glaukos's (GKOS) buyout offer is unlikely, Marcus tells investors in a research note.
08/26/19
JPMS
08/26/19
NO CHANGE
Target $90
JPMS
Overweight
Glaukos selloff brings 'notable buying opportunity,' says JPMorgan
JPMorgan analyst Robbie Marcus sees a "notable buying opportunity" following the post-earnings weakness in shares of Glaukos (GKOS). Fundamentals in the underlying business remain strong, the company's pipeline of products remains solid, and management remains confident in the Avedro (AVDR) deal, Marcus tells investors in a research note. He sees a "highly favorable" risk/reward for shares of Glaukos entering late 2019 and 2020. The analyst keeps an Overweight rating on the shares with a $90 price target.
09/12/19
PIPR
09/12/19
NO CHANGE
Target $80
PIPR
Overweight
Piper says buy Glaukos as Avedro deal has 'homerun potential'
Piper Jaffray analyst Matt O'Brien believes Glaukos' (GKOS) acquisition of Avedro (AVDR) has "homerun potential." In the near-term, Avedro should quadruple Glaukos' total addressable market to $4B and accelerate its revenue growth in 2020, "plugging the gap ahead of iDose," O'Brien tells investors in a research note following a deep dive analysis. Longer term, Glaukos is "putting together the pieces of what could become an ophthalmology powerhouse," addressing a potential opportunity of greater than $40B, adds the analyst. He "strongly" encourages investors to take a look at the Glaukos story today as he sees at least $80 per share of value in just the base businesses alone. O'Brien reiterates an Overweight rating on the shares with an $80 price target.
SWAV ShockWave Medical
$29.72

-1.97 (-6.22%)

04/01/19
BOFA
04/01/19
INITIATION
Target $37
BOFA
Neutral
ShockWave Medical initiated with a Neutral at BofA/Merrill
BofA/Merrill analyst Bob Hopkins initiated ShockWave Medical with a Neutral and $37 price target citing valuation.
06/18/19
ADAM
06/18/19
NO CHANGE
Target $65
ADAM
Buy
ShockWave Medical price target raised to $65 from $50 at Canaccord
Canaccord analyst Jason Mills raised his price target on ShockWave Medical to $65 from $50 as he remains bullish due to a myriad of positive updates on the firm's proprietary IVL platform. TAVR remains the company's largest near-term opportunity but as the technology has continually improved, the percentage of TAVR cases able to be performed via a transfemoral access route has increased. Mills reiterated his Buy rating on ShockWave Medical shares.
04/01/19
WELS
04/01/19
INITIATION
Target $33
WELS
Market Perform
ShockWave Medical initiated with a Market Perform at Wells Fargo
Wells Fargo analyst Larry Biegelsen started coverage of ShockWave Medical with a Market Perform rating and a $33 price target. The analyst believes the company's intravascular lithotripsy is an innovative technology that has several key advantages over the competition, and that it will be able to both grow the market opportunity for calcium modification devices and take share from the atherectomy players. That stated, at current valuations, Biegelsen does not see the potential for meaningful multiple expansion.
04/01/19
MSCO
04/01/19
INITIATION
Target $32
MSCO
Equal Weight
Morgan Stanley starts ShockWave Medical at Equal Weight, citing valuation
As previously reported, Morgan Stanley analyst David Lewis initiated ShockWave Medical with an Equal Weight rating, citing a valuation that he sees as reflecting a balance of the company's significant opportunity and the risks. While Shockwave is "a disruptive technology poised for rapid adoption," it is clear from the stock's performance since the IPO that investors have looked far into the future and shown great comfort in market development and physician adoption, said Lewis, who set a $32 price target on the shares.
XENT Intersect ENT
$16.54

-0.19 (-1.14%)

08/02/19
GUGG
08/02/19
DOWNGRADE
GUGG
Neutral
Intersect ENT downgraded to Neutral from Buy at Guggenheim
08/02/19
GUGG
08/02/19
DOWNGRADE
GUGG
Neutral
Intersect ENT downgraded to Neutral after 'disappointing' Q2 at Guggenheim
As previously reported, Guggenheim analyst Chris Pasquale downgraded Intersect ENT to Neutral from Buy after the company reported Q2 results that he called "disappointing." Sales decelerated sharply and guidance was also cut for the second time this year, noted Pasquale, who remains optimistic that new CEO Tom West will be able to solve execution-related issues but that it may be another 6-9 months before momentum improves.
08/02/19
PIPR
08/02/19
DOWNGRADE
Target $17
PIPR
Neutral
Intersect ENT downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Matt O'Brien downgraded Intersect ENT to Neutral from Overweight and lowered his price target for the shares to $17 from $30. The company reported Q2 revenue results that were light of estimates, but the big news was management meaningfully reducing revenue guidance for the year to flat growth from 2019, O'Brien tells investors in a research note. He believes the turnaround of the business has low visibility and that it will likely take longer than expected "as is typical for a new management team."
07/10/19
NORL
07/10/19
UPGRADE
Target $20
NORL
Market Perform
Intersect ENT upgraded to Market Perform at Northland
As previously reported, Northland analyst Suraj Kalia upgraded Intersect ENT to Market Perform from Underperform. Though the ratings change does not reflect a fundamental change in outlook, the stock has fallen to the analyst's unchanged price target of $20 since the company's Q1 report, Kalia said.

TODAY'S FREE FLY STORIES

CIEN

Ciena

$40.89

5.44 (15.35%)

12:00
12/12/19
12/12
12:00
12/12/19
12:00
Hot Stocks
Ciena rises 15.4% »

Ciena is up 15.4%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

DBD

Diebold

$9.93

2.175 (28.05%)

12:00
12/12/19
12/12
12:00
12/12/19
12:00
Hot Stocks
Diebold rises 28.4% »

Diebold is up 28.4%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRX

Amneal Pharmaceuticals

$5.21

1.725 (49.50%)

12:00
12/12/19
12/12
12:00
12/12/19
12:00
Hot Stocks
Amneal Pharmaceuticals rises 49.1% »

Amneal Pharmaceuticals is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PKI

PerkinElmer

$95.54

1.19 (1.26%)

11:56
12/12/19
12/12
11:56
12/12/19
11:56
Hot Stocks
FDA authorizes PerkinElmer test to aid in newborn screening for DMD »

The U.S. Food and Drug…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,754.57

5.46 (0.31%)

11:56
12/12/19
12/12
11:56
12/12/19
11:56
Periodicals
Breaking Periodicals news story on Amazon.com »

Amazon.com announces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:55
12/12/19
12/12
11:55
12/12/19
11:55
General news
Treasury's $75 B 4- and 8-week bill auctions garnered mixed results »

Treasury's $75 B 4-…

11:55
12/12/19
12/12
11:55
12/12/19
11:55
Conference/Events
William Blair financial services/insurance analyst to hold a luncheon »

Financial…

11:55
12/12/19
12/12
11:55
12/12/19
11:55
Conference/Events
William Blair software/IT services to hold a group luncheon »

Enterprise Software &…

TOL

Toll Brothers

$39.55

-0.565 (-1.41%)

, DHI

D.R. Horton

$54.73

-1.17 (-2.09%)

11:51
12/12/19
12/12
11:51
12/12/19
11:51
Recommendations
Toll Brothers, D.R. Horton analyst commentary  »

Toll Brothers added to…

TOL

Toll Brothers

$39.55

-0.565 (-1.41%)

DHI

D.R. Horton

$54.73

-1.17 (-2.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALV

Autoliv

$85.31

2.14 (2.57%)

11:48
12/12/19
12/12
11:48
12/12/19
11:48
Conference/Events
Autoliv management to meet with Mizuho »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

AAPL

Apple

$269.52

-1.19 (-0.44%)

11:46
12/12/19
12/12
11:46
12/12/19
11:46
Periodicals
Apple supplier reaches agreement for $736M bailout, Bloomberg reports »

Apple supplier Japan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IRBT

iRobot

$49.39

3.15 (6.81%)

11:45
12/12/19
12/12
11:45
12/12/19
11:45
Options
iRobot call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:45
12/12/19
12/12
11:45
12/12/19
11:45
Conference/Events
The Empire Club of Canada holds a luncheon meeting »

The Bank of Canada…

COUP

Coupa Software

$137.90

-6.21 (-4.31%)

11:43
12/12/19
12/12
11:43
12/12/19
11:43
Conference/Events
Coupa Software management to meet with Needham »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 17

    Dec

  • 06

    Jan

FIVN

Five9

$65.32

-0.08 (-0.12%)

11:42
12/12/19
12/12
11:42
12/12/19
11:42
Conference/Events
Five9 management to meet with Needham »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 17

    Dec

FORM

FormFactor

$25.31

1.54 (6.48%)

11:41
12/12/19
12/12
11:41
12/12/19
11:41
Conference/Events
FormFactor management to meet with Needham »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

11:39
12/12/19
12/12
11:39
12/12/19
11:39
Conference/Events
JPMorgan biotechnology analysts to hold an analsyt/industry conference call »

Biotech Analysts Kasimov,…

11:34
12/12/19
12/12
11:34
12/12/19
11:34
Conference/Events
JPMorgan payment/IT services analyst to hold an analyst/industry conference call »

Payments, Processors…

ICE

IntercontinentalExchange

$91.48

-0.87 (-0.94%)

11:33
12/12/19
12/12
11:33
12/12/19
11:33
Hot Stocks
ICE announces first block trade of Bakkt Bitcoin Monthly Options »

Intercontinental Exchange…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

BILL

Bill.com

$0.00

(0.00%)

11:30
12/12/19
12/12
11:30
12/12/19
11:30
Syndicate
Breaking Syndicate news story on Bill.com »

Bill.com opens at $37.25,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

11:28
12/12/19
12/12
11:28
12/12/19
11:28
Conference/Events
JPMorgan beverage/household analyst to hold an analyst/industry conference call »

Beverage, Household &…

BILL

Bill.com

$0.00

(0.00%)

11:27
12/12/19
12/12
11:27
12/12/19
11:27
Syndicate
Breaking Syndicate news story on Bill.com »

Bill.com indicated to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

PCG

PG&E

$11.27

-0.86 (-7.09%)

11:25
12/12/19
12/12
11:25
12/12/19
11:25
Options
PG&E call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

LUV

Southwest

$55.10

1.12 (2.07%)

11:25
12/12/19
12/12
11:25
12/12/19
11:25
Conference/Events
The Wings Club to hold a luncheon meeting »

The Wings Club of New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 23

    Jan

GNFT

Genfit

$16.82

1.44 (9.36%)

11:25
12/12/19
12/12
11:25
12/12/19
11:25
Conference/Events
Roth Capital healthcare analyst to hold an analyst/industry conference call »

Healthcare Analyst Rahimi…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 18

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.